Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer

PURPOSE: The effects of immune checkpoint inhibitors have been reported to be linked with immune-related adverse events (irAEs). In patients with advanced non-small-cell lung cancer, who tested positive for programmed death-ligand 1 (PD-L1), pembrolizumab, an immune checkpoint inhibitor can be used...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Lung Cancer (Auckl)
Autori principali: Noguchi, Susumu, Suminaga, Keiichiro, Kaki, Takahiro, Kawachi, Hiroaki, Fukao, Akari, Terashita, Satoshi, Horikawa, Sadao, Ikeue, Tatsuyoshi, Sugita, Takakazu
Natura: Artigo
Lingua:Inglês
Pubblicazione: Dove 2020
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7367935/
https://ncbi.nlm.nih.gov/pubmed/32765147
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/LCTT.S254146
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi